The aim of this work was to assess the viability of some commercial probiotics after 14 exposure to gastric acid and the possibility of modifying these formulations for 15 delivery into the distal parts of the intestines. Gastrointestinal tolerance testing was 16 conducted for three commercial probiotics and an in-house freeze-dried 17
Introduction 37
In recent years, there has been an increased interest in the use of probiotics with 38 several probiotic products on the market with various delivery mechanisms. The 39 concept of probiotics emerged from the early 20 th century when the Russian 40 immunologist Elie Metchnikoff observed that Bulgarian peasant farmers had long life-41 spans. He suggested this was due to the consumption of large quantities of 42 fermented milk, rich in lactobacilli. Metchnikoff suggested that pathogens present in 43 the intestine released toxins which were poisonous to the body and the consumption 44 of fermented milk helped alleviate the effects of these pathogens and their toxins 45 (Fuller, 1991 , Vasiljevic and Shah, 2008 , Dixon, 2002 . The Food and Agriculture 46
Organisation of the United Nations, and World Health Organisation jointly describe 47 probiotics as live microorganisms that when administered in adequate amounts 48 confer a health benefit on the host (FAO/ WHO, 2002) . 49
For an organism to be considered as a probiotic, it must have been documented to 50 have a health benefit (Sanders, 2009 ). Several health claims have been attributed to 51 probiotics, some of these health claims are towards gastrointestinal health whereas 52 others are intended for systemic benefits contributing towards overall general 53 wellbeing. Gastrointestinal health claims attributed to probiotics include the 54 alleviation of lactose intolerance, prevention of antibiotic-associated diarrhoea, and 55 management of inflammatory bowel disease (Tung et The recent increased interest in probiotics also stems from the greater awareness of 62 the human microbiome and its potential applications. An increased realisation of the 63 need for alternatives to antibiotics has partly contributed to this. Even though 64 antibiotics have been around for over 50 years, hospital infection rates are not 65 declining and multi-drug resistant bacteria continue to emerge creating a major 66 public health problem as a result (Broeckx et al., 2016 , Teughels et al., 2011 Formulating probiotics can be challenging since product viability must be maintained 86 during formulation and after consumption by consumers. Formulating products that 87 can withstand the harshness of the gastrointestinal tract and target them to the 88 intestines is currently receiving great interest as are formulation processes that are 89 not deleterious to organisms (Kailasapthy, 2002 , Mortazavian et al., 2007 . The aim 90 of this work was, therefore, to assess the viability of some commercial probiotics 91 after exposure to gastric acid and the possibility of modifying these formulations. The 92 modification approach used here was the Phloral 
Materials 101
Pepsin, trehalose, xylitol, sucrose, and triton X-100 were purchased from Sigma, UK. 102
Dulbecco's Modified Eagle Medium, heat-inactivated foetal bovine serum, 103 phosphate-buffered saline (PBS), 1% non-essential amino acid, and trypsin-ethylene 104 diamine tetraacetic acid were from Gibco, UK. de Man, Rogosa and Sharpe (MRS) 105 agar and broth were from Oxoid, UK. Hydrochloric acid was purchased from VWR, 106 UK. Sodium chloride was purchased from Fisher Scientific, UK. 107
Three commercial probiotic products were bought from a health food shop and 108
analysed. The choice of probiotics was limited to products that contain only 109 lactobacilli strains; these are represented here as Products A, B, and C and their 110 composition is indicated in Table 1 . These probiotics were selected because they 111 contain strains common to most probiotic products, and so the results have wide 112
applicability. An in-house probiotic was also prepared by freeze-drying Lactobacillus 113 acidophilus LA 5. 114 
Preparation of freeze-dried probiotic 117
An in-house freeze-dried probiotic formulation was prepared for comparison with the 118 commercial products. Lactobacillus acidophilus LA5 was used as the model probiotic 119 strain with 10% sucrose or 10% trehalose used as protectants. 120
Cultivation of microorganism and preparation of bacterial culture 121
Lactobacillus acidophilus was initially grown on MRS (de Man, Rogosa, and Sharpe) 122 agar and incubated under anaerobic conditions for 48 hours at 37 ºC. A few colonies 123 were taken and used to inoculate 7 mL of MRS broth to create a starter culture and 124 incubated for 24 hours. 99 mL of fresh MRS broth was inoculated with 1 mL of 125 starter culture to create a 1: 100 dilution and this was incubated for 24 hours. The 126 culture was then mixed using a magnetic stirrer and 30 mL each was dispensed into 
Evaluating viability of probiotic products 144
The contents of one capsule of each commercial probiotic were suspended in 5 mL 145 of PBS and vortexed for about 10 seconds and allowed to stand for 10 minutes and 146 vortexed once more for homogeneity. These were then serially diluted and plated 147 onto MRS agar. The agar plates were incubated at 37 o C under anaerobic conditions 148 for 48 hours after which colonies were counted. 100 mg was used for the prepared 149 freeze-dried formulation. 150 151
Evaluating the in vitro adhesion of probiotics to intestinal cells 152
The evaluation done here was similar to work carried out by Forestier et al. (2001) . 153
The growth medium used was Dulbecco's Modified Eagle Medium supplemented 154 with 10% of heat-inactivated foetal bovine serum and 1% non-essential amino acid. 155
The prepared medium was used to routinely grow Caco-2 cells in cell culture flasks 156 with surface area 75cm 2 or to seed cells in a well-plate. All cells were incubated at 157 37 o C in a humidified atmosphere of 5% CO 2 . 158
Caco-2 monolayers were seeded at a concentration of 2 x 10 5 cells per well in 12-159 well plates and incubated at 37 o C with humidified atmosphere of 5% CO 2 . Caco-2 160 cells were used in the late post-confluence stage with passage numbers between 39 161 and 54. Prior to adhesion testing, Caco-2 monolayers were washed twice with 1 mL 162 PBS; 1 mL of the cell culture growth medium was then added to each well. The 163 contents of one capsule of each commercial probiotic and 100 mg of the freeze-dried 164 L. acidophilus strain were suspended in 5 mL of PBS. These were serially diluted 165 such that the estimated bacterial numbers did not exceed the Caco-2 cell numbers. The contents of one capsule of each product were deposited into the SGF for 2 186 hours. All the media were pre-warmed to 37 o C prior to use and bacterial 187 enumeration was conducted at set times. To ensure the process was carried out at 188 37 o C with 50 rpm paddle movement as observed in USP dissolution testing, a hot 189 plate magnetic stirrer was used with temperature and speed set to 37 o C and 50 rpm 190 respectively. 50 mL of gastric media in sterile duran bottles were used. Aliquots were 191 taken at set times and enumeration of probiotic species conducted using MRS agar 192
plates. The plates were incubated for 48 hours afterwards under anaerobic 193 conditions. 100 mg was used for the prepared freeze-dried formulation.9
Encapsulation of probiotics for site-specific delivery 195
Capsules were coated using Phloral 
Freeze-drying Lactobacillus acidophilus LA5 212
The freeze-dried formulations with the protectants yielded recoveries over 90%; a 213 complete loss of viability was observed when no protectant was added (Table 2) . 214 215 Freeze-drying is a procedure based on sublimation under high vacuum, this occurs 218 in three phases, i.e., freezing, primary drying, and secondary drying. protectants, they could recover only 13% and 34% viabilities respectively after 238 freeze-drying. They needed a combination of both amounts in addition to 18% 239 skimmed milk to obtain 83-85% survival rates. 240 241
Evaluating viability of product content 242
An evaluation of the content in each of the products analysed is shown in Figure 1 . acid, which is a weak acid and well tolerated by most probiotics as compared to 296 gastric acid which is, 0.1 M HCl, a strong acid. In a study conducted to evaluate 297 some probiotic strains to gastric acid, only 1 of 15 probiotic strains was considered to 298 be intrinsically resistant to gastric acid, the remaining strains were all killed (Charteris 299 et al., 1998) . 300
When the probiotics were exposed to SGF, there was a significant drop in viability. 
